{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:02:59Z","timestamp":1776502979761,"version":"3.51.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The impact of lipid-lowering medications on chronic kidney disease (CKD) remains a subject of debate. This Mendelian randomization (MR) study aims to elucidate the potential effects of lipid-lowering drug targets on CKD development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted 11 genetic variants encoding targets of lipid-lowering drugs from published genome-wide association study (GWAS) summary statistics, encompassing LDLR, HMGCR, PCSK9, NPC1L1, APOB, ABCG5\/ABCG8, LPL, APOC3, ANGPTL3, and PPARA. A Mendelian randomization analysis was conducted targeting these drug-related genes. CKD risk was designated as the primary outcome, while estimated glomerular filtration rate (eGFR) and blood urea nitrogen (BUN) were assessed as secondary outcomes. Additionally, mediation analysis was performed utilizing 731 immune cell phenotypes to identify potential mediators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta-analysis revealed a significant association between ANGPTL3 inhibitors and a reduced risk of CKD (OR [95% CI] = 0.85 [0.75-0.96]). Conversely, LDLR agonists were significantly linked to an increased risk of CKD (OR [95% CI] = 1.11 [1.02-1.22]). Regarding secondary outcomes, lipid-lowering drugs did not significantly affect eGFR and BUN levels. Mediation analysis indicated that the reduction in CKD risk by ANGPTL3 inhibitors was mediated through modulation of the immune cell phenotype, specifically HLA-DR on CD14+ CD16+ monocytes (Mediated proportion: 4.69%; Mediated effect: -0.00899).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Through drug-targeted MR analysis, we identified a causal relationship between lipid-lowering drug targets and CKD. ANGPTL3 and LDLR may represent promising candidate drug targets for CKD treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1434145","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:12:15Z","timestamp":1736831535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney diseases: Off J Natl Kidney Foundation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","year":"2024","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070539","article-title":"Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000","volume":"16","author":"Coresh","year":"2005","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2013measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.09805.x","article-title":"The kidney, a cardiovascular risk marker, and a new target for therapy","volume":"98","author":"de Zeeuw","year":"2005","journal-title":"Kidney Int Supplement"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121273","article-title":"International comparison of the relationship of chronic kidney disease prevalence and ESRD risk","volume":"17","author":"Hallan","year":"2006","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00757.x","article-title":"Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years","volume":"68","author":"Chen","year":"2005","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.11.015","article-title":"United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States","volume":"59","author":"Collins","year":"2012","journal-title":"Am J Kidney diseases: Off J Natl Kidney Foundation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/nu11040722","article-title":"Lipid accumulation and chronic kidney disease","volume":"11","author":"Gai","year":"2019","journal-title":"Nutrients"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32691","article-title":"Adiponectin regulates albuminuria and podocyte function in mice","volume":"118","author":"Sharma","year":"2008","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jclinpath-2021-207719","article-title":"Hypertriglyceridaemia: an update","volume":"75","author":"Wierzbicki","year":"2022","journal-title":"J Clin pathology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab876","article-title":"New therapies for primary hyperlipidemia","volume":"107","author":"Aguilar-Salinas","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0825","article-title":"The diagnosis and treatment of hypertriglyceridemia","volume":"116","author":"Parhofer","year":"2019","journal-title":"Deutsches Arzteblatt Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062444","article-title":"Management of statin intolerant patients in the era of novel lipid lowering therapies: A critical approach in clinical practice","volume":"12","author":"Bosco","year":"2023","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Internal Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy159","article-title":"Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials","volume":"34","author":"Idzerda","year":"2019","journal-title":"Nephrology dialysis transplantation: Off Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet (London England)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2021.1915799","article-title":"Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Zhao","year":"2021","journal-title":"Renal failure"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041302","article-title":"Mendelian randomization","volume":"12","author":"Birney","year":"2022","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-2573-6_1","article-title":"Target discovery for drug development using mendelian randomization","volume":"2547","author":"Evans","year":"2022","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v27:8","article-title":"Mendelian randomization: using genes as instruments for making causal inferences in epidemiology","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1329847","article-title":"Potential causal association between aspirin use and erectile dysfunction in European population: a Mendelian randomization study","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PloS Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx561","article-title":"LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation","volume":"34","author":"Machiela","year":"2018","journal-title":"Bioinf (Oxford England)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0985","article-title":"LDtrait: an online tool for identifying published phenotype associations in linkage disequilibrium","volume":"80","author":"Lin","year":"2020","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030678","article-title":"Risk factors of chronic kidney disease progression: between old and new concepts","volume":"13","author":"Mallamaci","year":"2024","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0407-x","article-title":"A catalog of genetic loci associated with kidney function from analyses of a million individuals","volume":"51","author":"Wuttke","year":"2019","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1038\/ncomms10023","article-title":"Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function","volume":"7","author":"Pattaro","year":"2016","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors","volume":"30","author":"Burgess","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.2016.40.issue-4","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int J Epidemiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1427318","article-title":"Assessing the role of statin therapy in bladder cancer: evidence from a Mendelian Randomization study","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ece3.v10.20","article-title":"A contrast of meta and metafor packages for meta-analyses in R","volume":"10","author":"Lortie","year":"2020","journal-title":"Ecol evolution"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/postmj\/qgae163","article-title":"Causal relationship between benign prostatic hyperplasia and prostate cancer: a bidirectional Mendelian randomization analysis","author":"Zhang","year":"2024","journal-title":"Postgraduate Med J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"109656","DOI":"10.1016\/j.intimp.2022.109656","article-title":"Minnelide combined with Angptl3 knockout completely protects mice with adriamycin nephropathy via suppression of TGF-\u03b21-Smad2 and p53 pathways","volume":"115","author":"Ji","year":"2023","journal-title":"Int immunopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41419-023-06124-0","article-title":"Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis","volume":"14","author":"Ji","year":"2023","journal-title":"Cell Death disease"},{"key":"B44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12944-022-01700-3","article-title":"ANGPTL3 is involved in kidney injury in high-fat diet-fed mice by suppressing ACTN4 expression","volume":"21","author":"Li","year":"2022","journal-title":"Lipids Health disease"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228399","article-title":"The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12944-018-0659-y","article-title":"New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases","volume":"17","author":"Su","year":"2018","journal-title":"Lipids Health disease"},{"key":"B47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12944-023-01993-y","article-title":"Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets","volume":"23","author":"Chen","year":"2024","journal-title":"Lipids Health disease"},{"key":"B48","first-page":"19","article-title":"Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis","volume":"85","author":"Go","year":"2012","journal-title":"Yale J Biol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.113","article-title":"Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12122083","article-title":"Oxidative stress induced by lipotoxicity and renal hypoxia in diabetic kidney disease and possible therapeutic interventions: targeting the lipid metabolism and hypoxia","volume":"12","author":"Chae","year":"2023","journal-title":"Antioxidants (Basel Switzerland)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat Rev Nephrology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051360","article-title":"Unraveling the crosstalk between lipids and NADPH oxidases in diabetic kidney disease","volume":"15","author":"Njeim","year":"2023","journal-title":"Pharmaceutics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146920","article-title":"PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR","volume":"11","author":"Rogacev","year":"2016","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/eci.2016.46.issue-9","article-title":"PCSK9 in diabetic kidney disease","volume":"46","author":"Elewa","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1159\/000365935","article-title":"Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy","volume":"40","author":"Konarzewski","year":"2014","journal-title":"Am J nephrology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.12.030","article-title":"Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels","volume":"233","author":"Abujrad","year":"2014","journal-title":"Atherosclerosis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int Urol nephrology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.krcp.2013.08.001","article-title":"Proinflammatory CD14(+)CD16(+) monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease","volume":"32","author":"Lee","year":"2013","journal-title":"Kidney Res Clin practice"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/sji.2016.84.issue-4","article-title":"Presence of HLA-DR molecules and HLA-DRB1 mRNA in circulating CD4(+) T cells","volume":"84","author":"Revenfeld","year":"2016","journal-title":"Scandinavian J Immunol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1434145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:12:23Z","timestamp":1736831543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1434145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":60,"alternative-id":["10.3389\/fendo.2024.1434145"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1434145","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1434145"}}